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Abstract 
Vascular disease is a leading cause of death and disability worldwide. Current surgical intervention 
and treatment options for vascular diseases have exhibited limited long-term success, emphasizing 
the need to develop advanced treatment paradigms for early detection and more effective 
treatment of dysfunctional cells in a specific blood vessel lesion. Advances in targeted nanoparticles 
mediating cargo delivery enables more robust prevention, screening, diagnosis, and treatment of 
vascular disorders. In particular, nanotheranostics integrates diagnostic imaging and therapeutic 
function into a single agent, and is an emerging platform towards more effective and localized 
vascular treatment. This review article highlights recent advances and current challenges 
associated with the utilization of targeted nanoparticles for real-time diagnosis and treatment of 
vascular diseases. Given recent developments, nanotheranostics offers great potential to serve as 
an effective platform for targeted, localized, and personalized vascular treatment. 
Key words: vascular diseases, nanotheranostics 
Introduction 
Vascular disease is a leading cause of death in 
the developed world. According to a 2016 Statistics 
Update from American Heart Association, one in 
three Americans dies due to cardiovascular disease 
[1]. Major vascular diseases include atherosclerosis, 
aneurysms, stroke, thrombosis, coronary artery 
disease (CAD), and peripheral artery disease (PAD). 
Although significant differences exist in terms of the 
precise nature and location of these disorders, they 
share many spatiotemporal cellular and molecular 
mechanisms [2]. 
Conventional vascular therapies utilize oral, 
parenteral, intravenous or intra-arterial 
administration of small molecule drugs and 
non-preferentially affect both diseased and normal 
cells. Unwanted systemic side effects and less drug 
accumulation at target sites occur as a result. 
Conventional approaches are also limited with 
respect to rapid drug clearance from circulation and 
drug instability [3]. Surgical procedures such as 
angioplasty, stenting, atherectomy, stent-grafting and 
bypass grafting are also commonly employed [4]. 
Small molecule drugs have been incorporated into 
stents, balloon devices, and vascular grafts with 
marginal improvement in therapeutic efficacy, but 
these approaches lack imaging and therefore 
diagnostic capabilities [5]. Non-invasive imaging 
techniques such as conventional digital subtraction 
angiography, computed tomography angiography 
(CTA), magnetic resonance angiography (MRA), and 
duplex ultrasound are used to aid these approaches 
[6]. While these imaging modalities have improved 
diagnostic capabilities, further improvement is 
needed with respect to over-estimation of stenosis 
and longer imaging time of calcified arterial stenosis 
[7]. Therefore, the field of vascular disease requires 
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more advanced engineering of therapeutic and 
imaging modalities [8].  
Nanotechnology in medicine 
Recent advances in nanotechnology enables 
timely detection, prevention and treatment of disease 
[9, 10]. These studies are focused toward the 
development of new methods either for incorporation 
or encapsulation of therapeutics, imaging agents and 
targeting ligands to the nanoparticles. In recent years, 
target-specific engineered nanoparticles have 
exhibited substantial improvement over conventional 
treatment options in terms of site-specific localization 
and reduced side effects [11].  
Nanotechnology uses particles with spherical, 
cylindrical, plate-like and other morphologies in an 
average size ranging of around ten to several hundred 
nanometers (nanoparticles) for encapsulation and 
delivery of small molecule drugs and/or imaging 
agents. Nanoparticles have inspired considerable 
research interest as controlled and sustained drug 
delivery vehicles due to their numerous potential 
benefits. Desirable characteristics include protection 
of drugs against degradation via stable encapsulation, 
ability to deliver poorly soluble drugs, limited 
toxicity, and site-specific targeting capabilities. 
Representative nanomaterials include polymeric 
micelles, nanospheres, and dendrimers, quantum 
dots, ultra-small superparamagnetic iron oxides 
(USPIOs), liposomes, and antibodies. These 
nanoparticles contain surface charge and functional 
groups which may potentially impact their circulation 
and macrophage uptake, thereby influencing 
bio-distribution and delivery of payload at the 
targeted site. In general, neutral and negatively 
charged particles have reduced plasma protein 
adsorption and have a low rate of nonspecific cellular 
uptake whereas positive charged particles are 
preferentially uptaken by macrophages [12]. 
Therefore, nanoparticles can be engineered with an 
optimum surface charge (e.g. positive, neutral or 
negative), charge density and targeting ligands in 
order to extend circulation time, reduce non-specific 
clearance, and enable effective targeting to a desired 
location [13]. 
Most nanomaterial studies have been either 
focused on development of controlled drug delivery 
or imaging agents for screening, diagnosis, and 
therapeutic monitoring. A separate therapeutic 
delivery or diagnosis-focused nanoparticle approach 
performs well for some particular functions but is 
limited with respect to simultaneous real-time 
monitoring of disease progression and therapeutic 
treatment. Therefore, multifunctional nanoparticles 
combined with therapeutic targeting and diagnostic 
capability is advantageous for real-time disease 
treatment. Fortunately, extensive research in 
nanomedicine has afforded the ability to precisely 
control nanoparticle design features such as size, 
surface charge and morphology through either the 
attachment or incorporation of biological and 
chemical agents within nanoparticles. These versatile 
nanoparticle features allow for the integrated design, 
synthesis and fabrication of single agents combined 
with therapeutic and diagnostic functions [14, 15] 
(Fig. 1). 
 
 
Figure 1. Schematic illustration of theranostic nanoparticles (e.g., micelles, 
liposomes, nanospheres, dendrimers, quantum dots, iron oxide particles, etc.) 
embedded with therapeutic and imaging agents. 
 
 In 2002, John Funkhouser coined this approach 
theranostics to describe ongoing efforts to develop 
such nanoparticle systems for personalized medicine. 
These multifunctional nanoparticles are called 
nanotheranostics, which are designed to enable 
simultaneous disease detection and treatment 
capabilities [16]. Nanotheranostics as a non-invasive 
and real-time approach provides a potential 
therapeutic tool for clinicians to simultaneously 
monitor drug release at targeted sites and assess its 
therapeutic function. Studies utilizing theranostic 
nanoparticles could help physicians to tailor drug 
doses for the individual patient in a more efficient 
manner. In this way, therapeutic benefit could be 
improved through a reduction in toxicity as well as 
drug costs [17]. Also, development of efficient 
theranostic vehicles requires an understanding about 
the underlying disease mechanisms for determining a 
theranostic agent’s targeting location, drug release 
and therapeutic efficacy [18]. To date, most 
nanomaterial research is focused on cancer targeting 
nanotheranostics [19], but research focused on 
nanotheranostics for vascular diseases such as 
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atherosclerosis, thrombosis and cerebrovascular 
amyloid angiopathy is an emerging field [20]. Several 
nanoparticle approaches have been investigated 
either for the treatment or diagnosis of atherosclerosis 
lesions [21] but this review article mainly focuses on 
specific approaches for vascular theranostic targeting.  
Recent strategies to design vascular 
theranostic nanomaterials 
Molecular mechanisms of vascular disease have 
been extensively studied and provide strategies to 
design specific nanomaterials targeted selectively to 
diseased cells and tissues. The cellular biomarker 
specific to endothelial cells (Integrin αVβ3, CAMS 
(ICAM, VCAM, and PECAM)), platelets (integrin’s 
GPIIb-IIIa, GPIa-IIa, GPVI, GPIb-IX-V, p-selectin), 
activated macrophages (scavenger receptors, oxidized 
LDL receptors) and smooth muscle cells with a 
pathological, synthetic phenotype can be used as 
cellular targets for identification of these disease at 
early stages. Non-cellular biomarkers include 
lipoproteins, annexins, fibrin, ECM proteins, MMPs, 
tissue factor, etc. [22]. Nanoparticles can be 
functionalized with specific ligands/antibodies/ 
peptides to target the specific vascular regions 
affected by inflammation, thrombosis, hyperlipidemia 
or oxidative injury. These research approaches for 
vascular nanotheranostics have been mostly designed 
to develop nanoparticles for treatment of 
atherosclerotic plaques, an underlying cause for most 
vascular diseases. Theranostic targeted nanoparticles 
with respect to specific cellular and non-cellular 
biomarkers are discussed in their respective disease 
sections.  
Atherosclerosis and nanoparticle 
approaches 
Atherosclerosis is an inflammatory vascular 
disease characterized by an accumulation of lipid-rich 
plaques within arteries [23]. Atherosclerosis occurs in 
arteries for the heart, brain, arms, legs, pelvis, and 
kidneys and underlies the medical conditions of CAD, 
aortic aneurysms, PAD, and chronic kidney disease 
(CKD). Atherosclerosis is initiated through an 
imbalance in lipid metabolism and a maladaptive 
immune response that further results in chronic 
inflammation within the arterial wall. Disease 
progression starts at an early stage of life that begins 
with formation of "fatty streaks", which can evolve 
unstable plaques enriched with macrophages and T 
lymphocytes, amongst other cell types. The beginning 
stage is characterized by adhesion of white blood cells 
to the activated endothelial monolayer, their directed 
migration into the intima, maturation of monocytes 
into macrophages, and formation of foam cells 
through lipid uptake. The dysfunctional and 
damaged endothelium further undergoes a series of 
events for gradual development of atherosclerosis. 
Progression of the lesion includes the migration of 
smooth muscle cells (SMCs) to the intima, the 
proliferation of resident intimal and media-derived 
SMCs, and over-production of extracellular matrix 
(ECM) components such as elastin, collagen and 
proteoglycans. This process results in accumulation of 
extracellular lipids in advanced lesions through 
apoptosis of plaque macrophages and SMCs [23].  
Macrophages are one of the most important 
factors in atherosclerotic progression and are known 
to release inflammatory factors and chemokines that 
affect healthy blood vessels and thus contribute to 
neointimal hyperplasia or restenosis following 
interventional therapies [24]. A vast majority of 
macrophages in atherosclerotic lesions are produced 
from local macrophage proliferation instead of 
inflammatory monocyte recruitment from peripheral 
blood. Therefore, targeting macrophage proliferation 
could be a new promising strategy to treat 
atherosclerosis lesions [25, 26].  
Photo-induced inflammatory cell ablation using 
a macrophage-targeted nanoparticle is being used as a 
therapeutic approach for treatment of atherosclerosis. 
These nanoparticles are toxic when activated by 
certain wavelengths of light, thereby reducing 
off-target side effects. McCarthy et al. developed 
macrophage-targeting magnetic fluorescence 
nanoparticles to treat atherosclerosis and in-stent 
restenosis [27]. In this study, magnetic fluorescent 
nanoparticles (MFNPs) were prepared by conjugation 
of 10 kDa dextran-coated magnetic nanoparticles with 
AF-750 NR dye. In order to impart photodynamic 
therapy functionality to MFNPs, a photosensitizer, 
5-(4-carboxyphenyl)-10,15,20-triphenyl-2,3-dihydroxy
chlorin (TPC), was covalently conjugated to the 
primary amines of MFNP (Fig. 2). MFNPs were stable 
in DPBS (pH 7.4) for months without losing their 
detection capability through MRI and fluorescence 
imaging methodologies. Upon excitation of MFNPs at 
646 nm, photosensitizer-generated singlet oxygen 
species specifically killed the macrophages without 
affecting the neighboring normal cells. The 
macrophages demonstrated a time-dependent 
increase in uptake of MFNPs by flow cytometry 
analysis. In vivo application of these nanoparticles also 
demonstrated high macrophage uptake, efficient cell 
killing, and safe monitoring of its spatial distribution 
by both MRI and near-infrared fluorescence imaging. 
In another article from the same group, a 
dextran-coated iron oxide based magneto-fluorescent 
nanoagent was synthesized by conjugation of 
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AlexaFluor 750 and meso-tetraphenylchlorin 
derivative for near-infrared fluorescent imaging and 
generation of singlet oxygen, respectively [28]. The 
theranostic nanoagents were engulfed by phagocytic 
macrophages and exhibited higher photo toxicity 
compared to the traditional chlorin derivatives. The 
efficacy of nanoagents was further tested in an apoE−/- 
mouse animal model. The nanoagents accumulated 
preferentially inside the atherosclerotic lesions and 
caused photo-induced apoptosis of phagocytic 
macrophages [28]. 
Inflammatory macrophages secrete matrix- 
disorganizing proteases (e.g., cathepsins and matrix 
metalloproteinases) at atherosclerotic sites, which can 
cause thromboembolic stroke or myocardial infarction 
through atheromata-induced rapture of vulnerable 
plaques [29]. Initially, Choi et al. investigated the 
anti-tumor effect of cathepsin B activatable chlorin e6 
(Ce6)-functionalized poly-l-lysine grafted with 
monomethoxy-polyethylene glycol (L-SR15) 
nanoparticles through protease–mediated 
photodynamic therapy [30]. Next, an in vitro study 
from Lee et al. first tested the aforementioned 
theranostic photodynamic agent for proteolytic 
cleavage induced death of macrophages upon light 
illumination by generating highly reactive oxygen 
species and further studied the effects of atorvastatin 
and clopidogrel (anti-atherosclerotic drugs) on the 
effectiveness of photosensitization in cultured murine 
macrophage RAW 264.7 cells [31]. These drugs didn’t 
influence cellular uptake of L-SR15 but interfered 
with the in vitro photosensitization effect. In a 
subsequent study from the same group, Shon et al. 
tested the diagnostic and therapeutic efficacy of 
cathepsin-B activatable L-SR15 in a 30 week-old 
apolipoprotein E knock-out atheromata mouse model 
for the selective apoptotic attenuation of macrophages 
and a reduction in catB protease activity [32]. An 
increase in fluorescence signal from the atheromata 
region of the L-SR15 group compared to other 
controls indicated CasB-mediated release of the 
photosensitizer and preferential accumulation in 
plaques. L-SR15 didn’t cause systemic or 
neurobehavioral cytotoxicity after photodynamic 
therapy. Histological images confirmed the selectivity 
of the L-SR15–based PDT treatment for killing 
macrophages without affecting smooth muscle cells 
[32].  
5-Aminolevulinic acid (ALA) is an endogenous 
photodynamic metabolite, which transforms into an 
active photosensitizer porphyrin IX (PPIX) inside cells 
through a cellular heme biosynthetic pathway [33]. 
PPIX is a potent photosensitizer, which can be excited 
by red light of 635 nm for generation of singlet oxygen 
species. ALA-derived PPIX has been shown to 
accumulate especially in atherosclerotic plaques, and 
its fluorescence intensity can be positively correlated 
with the plaque macrophage content [34, 35]. To 
harness the photodynamic properties of ALA-derived 
PPIX for early diagnosis and therapy of 
atherosclerosis, Gonçalves et al., formulated 
PEGylated ALA gold nanoparticles (ALA:AuNPs) 
 
Figure 2. Macrophage-targeted theranostic nanoparticle (TNP) for photodynamic therapy of atherosclerosis disease. A) Aqueous solution of TNPs were stable for 
months without precipitation (pH 7.4) (left), and visualized through MRI (middle) and fluorescence imaging (0.01 mg Fe per mL) (right). B) Cellular uptake and 
light-induced phototoxicity of the TNPs (i) Flow cytometic analysis of time-dependent accumulation of TNPs as confirmed by cell-associated fluorescence (0.1 mg Fe 
per mL). (ii) Fluorescence microscopy image shows an uptake and intracellular localization of the TNPs after 3h incubation with RAW 264.7 cells (0.1 mg Fe per mL). 
(iii) Cell viability of human macrophages after incubation (1 h) with the respective nanoparticles (0.2 mg Fe per mL) and light treatment (42 mW cm−2, 7.5 J), as 
determined by a MTS assay. The TNP Dark experiment consisted of cells incubated with TNP that did not receive PDT treatment. Control cells were incubated with 
PBS. All results are relative to the control cells (100 %). (iv) Dose-dependent phototoxicity of TNP in RAW 264.7 cells after incubation (1 h) and light treatment (42 
mW cm−2, 7.5 J), as determined by the MTS assay. Reproduced with permission from[27]. 
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with an average size of 18 nm and pH 
(~5-8.0)-dependent zeta potential (10-40 mV) [36]. The 
injected ALA/AuNPs accumulated into 
atheromatous plaques in a rabbit model of 
atherosclerosis and their ALA was converted to PPIX. 
The isolated blood and feces of rabbit demonstrated 
an increase in the fluorescence intensity of porphyrin, 
indicating stable encapsulation of ALA into gold 
nanoparticles and further conversion to fluorescent 
PPIX upon photo-exposure [36].  
SIGNR1 is a principal receptor for uptake of 
microbial dextran polysaccharides by macrophages 
[28, 37]. To target macrophages through the dextran 
receptor, near infrared (NIR) light-responsive dextran 
conjugated hollow-type gold nanoparticles were 
synthesized with an average size of 60 nm and 5 nm 
shell thickness; and these NPs were studied for their 
efficacy as a theranostic agent in RAW 267.4 
macrophages [38]. The NPs were uptaken by 
macrophages through a phagocytosis mechanism, 
which were imaged by dark field microscopy. The 
uptaken NPs by macrophages were then exposed to a 
different dose of NIR light; and cell death was 
analyzed by flow cytometry. No cell death was 
observed for control conditions but exposed particles 
caused a particle dose-dependent death of 
macrophages either through late apoptosis or 
secondary necrosis in in vitro cell culture studies [38]. 
 Activated macrophages express CD44 as one of 
cell surface receptors, and are known to phagocytose 
[39, 40], which provides an opportunity for 
macrophage targeting through extracellular 
hyaluronates. To target macrophages through a 
hyaluronate receptor, Frédéric et al. used 
hyaluronate-decorated chitosan nanogels embedded 
with anionic photosensitizer for photo-thermal 
therapy of inflamed macrophage rich region [41]. 
Ce6-hyaluronate-chitosan nanogels were formulated 
in a size range between 40 and 140 nm, when 
measured by SEM, and exhibited a zeta potential of 
-41mV. Ce6-nanogels were preferentially uptaken 
either by murine RAW 264.7 or human THP-1 
macrophages but negligibly uptaken by murine 
fibroblasts. When loaded in nanogels, 
photosensitizers retained in the inflamed joints of 
rheumatoid arthritis mice over a longer period of time 
compared to the free photosensitizers. This 
photodynamic therapy also exhibited a reduction in 
macrophage induced inflammation compared to the 
control conditions [41]. 
Another recent study by Qin et al. used gold 
nanorods (Au NRs) with dimension of 60 x14 nm as a 
promising theranostic approach for local imaging and 
photo-thermal therapy of inflamed macrophages [42] 
(Fig. 3). Au NRs were rigorously characterized for 
their efficacy as a nanotheranostic vehicle through in 
vitro experiments such as CCK8 cytotoxicity assay, 
calcein AM/PI staining, their cellular uptake by flow 
cytometry, CT imaging, and photo-thermal ablation 
treatment. Silver staining and in vitro micro-CT 
imaging demonstrated a concentration dependent 
uptake of AuNRs by macrophages. Next, a femoral 
artery restenosis model in apolipoprotein E knockout 
(Apo E) mice was used to examine the performance of 
Au NRs. After photo-thermal therapy (PTT), 
histological examination of femoral arteries staining 
images confirmed an ablation of macrophage layer in 
Au NRs group compared to the controls [42].  
The uptake of USPIO by macrophages is widely 
used for non-invasive MRI assessment of 
inflammation in atherosclerotic plaques [43]. To study 
the effect of Angiotensin II (Ang II) infusion on 
chronic anti-inflammatory response, Morris et al. 
studied uptake of USPIO as a contrast agent for 
imaging of atherosclerotic plaque inflammation in 
aorta of apoE−/− mice [44]. Histological examination of 
the aortic root lesion area after SB-239063 treatment 
indicated co-localization of USPIO inside the 
macrophages. Their study also demonstrated a 
reduction in uptake of USPIO by inflamed 
macrophages in atherosclerotic plaque after an 
anti-inflammatory treatment with p38 MAPK 
inhibitor[44].  
To effectively target the collagen IV rich 
atherosclerosis plaques, Dong et al. prepared 
polymer-lipid hybrid nanoparticles embedded with 
ultra-small super paramagnetic iron oxide (USPIO) 
and paclitaxel and functionalized the particles with 
collagen targeting specific C11 polypeptide 
(UP-NP-C11) [45]. NPs with USPIO and paclitaxel 
were formulated through a nanoprecipitation method 
and showed an average diameter of 140 nm. 
UP-NP-C11 NPs demonstrated sustained and control 
release behavior of paclitaxel. To demonstrate the 
targeting ability of C11 polypeptide in an in vitro 
study, macrophages coated over collagen IV rich 
Matrigel demonstrated a significant higher 
accumulation of UP-NP-C11 NPs compared to the 
control UP-NP NPs. Therefore, UP-NP-C11 NPs 
exhibited a better growth inhibitory effect on 
macrophages and good MRI ability. In vivo studies 
further confirmed the significantly higher 
accumulation of UP-NP-C11 NPs in rabbit 
atherosclerotic plaques compared to the control 
conditions [45].  
In another approach, Dongjin et al. developed 
pH-responsive, doxorubicin (Dox)-loaded hyaluronic 
acid–polypyrrole nanoparticles (HA–PPyNPs) for 
fluorescence imaging and therapy of proliferating 
macrophages [46]. HA–PPyNPs were able to stably 
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maintain the fluorescence quenching in a high serum 
(50%) environment. HA–PPyNPs under acidic 
conditions were able to demonstrate the sustained 
release of Dox as compared to the physiological 
conditions. Next, HA–PPyNPs were utilized for in 
vitro live cell imaging to see the pH activated 
fluorescence imaging and release of 
DOX@HA–PPyNPs to macrophages. An effective 
uptake of HA–PPyNPs was demonstrated through an 
increase in fluorescence intensity inside the cytoplasm 
through pH triggered release of drug. The control 
HA–PPyNPs were cytocompatible but Dox loaded 
HA–PPyNPs exhibited significant toxicity to the raw 
macrophages. hVSMCs as control showed 90% 
viability with Dox loaded HA–PPyNPs but 60% 
macrophages were dead under similar treatment 
conditions indicated their selective targetability of 
NPs towards the macrophages. These results were 
mainly focused on in vitro conditions [46].  
Duivenvoorden et al. from the Mulder group 
recently developed a statin loaded high density 
lipoprotein (rHDL)-based nanoparticles for delivery 
of statins at atherosclerotic lesions [47]. Statin is 
classified as a 3-hydroxy-3-methylglutaryl coenzyme 
A reductase (HMGR) inhibitor which is widely 
prescribed as a serum LDL cholesterol-lowering drug 
with anti-inflammatory properties. However, their 
full benefits cannot be harnessed due to low systemic 
availability. In vitro, selective anti-inflammatory 
effects of statin-rHDL nanoparticles on macrophages 
were demonstrated through very low cell viability of 
macrophages compared to smooth muscle cells and 
hepatocytes under similar culture conditions for 48 
hours. When an apolipoprotein E-knockout mouse 
model of atherosclerosis was used, in vivo delivery of 
statin-rHDL nanoparticles was successfully 
demonstrated at the sites of atherosclerosis lesion and 
reduced the inflammation through targeting 
macrophages [47]. 
 
 
Figure 3. Gold nanorods (Au NRs) as a theranostic platform for imaging and photothermal therapy (PTT) of inflamed macrophages in a mouse model of femoral 
artery restenosis. (A, B) In vivo 3D micro-CT images of the femoral artery before (down; B) and after (up; A) intravenous injection of Au NRs. C, D) IR thermal images 
of Apo E mice injected with the Au NRs (the right mouse, indicated region 11) or saline (the left mouse, indicated region 12) via intravenous injection, respectively, 
irradiated with an 808 nm laser (2 W/cm2) at a time point of 0 (up; C) and 300 s (down; C). E) The temperature profiles in regions 11 and 12 as a function of irradiation 
time. F, G) The representative histological examination sections stained with CD68, of the corresponding ex vivo femoral artery restenosis regions, after irradiation 
for 10 min. Irradiation was done by an 808 nm laser with the safe power density of 2 W/cm2. H) Statistical analysis of the macrophage number between Au NRs with 
and without PTT. Scale bars indicate 100 μm. Reproduced with permission from [42]. 
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Vasa vasorum growth-mediated angiogenesis 
plays a crucial role in progression of atherosclerotic 
plaques and several tumor types [48]. To target 
endothelial cells through ανβ3 Integrin receptors, 
Winter et al. intravenously injected the ανβ3-targeting 
nanoparticles into a hyperlipidemic white rabbit 
model for non-invasive MRI imaging of molecular 
epitopes associated with angiogenesis [49]. Their 
follow-up study was designed to deliver 
anti-angiogenic drugs that could reduce or stop 
plaque progression and also allow for non-invasive 
assessment of intramural effectiveness of the 
treatment. ανβ3 integrin–targeted paramagnetic 
nanoparticles were loaded with an anti-angiogenic 
drug, fumagillin, and their efficacy was tested for 
site-specific, non-invasive, treatment of angiogenesis 
at an early stage of atherosclerosis [50]. NPs delivered 
the drug successfully and showed an anti-angiogenic 
response compared to controls, which was assessed 
through follow-up imaging of 
nanoparticle-accumulated areas. Adventitial 
angiogenic expansion of the vasa vasorum was also 
examined through microscopically and demonstrated 
a significant reduction in angiogenesis after 
introducing a first dose of ανβ3-targeted, 
fumagillin-loaded NPs in comparison to control 
conditions [50].  
To explore the use of nucleoside-lipid based 
solid-lipid nanoparticle (SLNs) as a theranostic for 
potential prevention of platelet activation and 
aggregation at the site of atherosclerosis site, Khalid et 
al. formulated SLNs through encapsulation of USPIO 
and drug (α-tocopherol or prostacyclin PGI2) either 
with positively (DiC16dT) or negatively charged 
(DOTAU, DOU- polyethylene glycol (PEG)) lipids 
[51]. A nanoprecipitation method was used for 
preparation of positively or negatively charged SLNs 
with an average size of 80 (ζ = +55) and 98 (ζ −27 mV) 
nm, respectively. SLNs showed colloidal stability at 
37 ºC for 2 days without any change in their particle 
diameter. Magnetic resonance relaxometry 
measurement of SLNs demonstrated better 
concentration-dependent relaxivity properties 
compared to the clinically used Feridex as a contrast 
agent. To achieve long circulation time, 
negatively-charged SLNs were pegylated through 
mixing between nucleo-lipids DOTAU, and 
DOU-PEG and loaded with prostacyclin (PGI2) drug. 
Platelet aggregation induced by adenosine 
5′-diphosphate (ADP) and thrombin 
receptor-activating peptide-6 (TRAP-6) at post 15 min 
and 3 h incubation was completely inhibited by 
PEGylated SLNs loaded with USPIO and prostacyclin 
PGI2, whereas SLNs without prostacyclin PGI2 
allowed full aggregation [51]. 
To selectively target atheroprone vasculature, 
Hofmeister et al. from the Sung and Harrison group 
used PREY peptide-conjugated DPHE liposomes as 
targeting nanoparticles (Fig. 4). PREY-targeted 
liposomes with an average hydrodynamic diameter of 
64 nm accumulated preferentially in endothelial cells 
in a partially occluded carotid artery and other areas 
of disturbed flow [52]. Proteomic analysis and 
immunoblotting indicated that fibronectin and 
Filamin A were preferentially bound by 
PREY-nanocarriers in vessels under disturbed flow. In 
additional experiments, PREY-nanocarriers were 
loaded with the nitric oxide synthase co-factor 
tetrahydrobiopterin (BH4) that was previously shown 
to be deficient in regions of disturbed flow [53]. This 
intervention increased vascular BH4 and reduced the 
vascular superoxide in the partially ligated artery in a 
wild-type mouse, reducing plaque burden in the 
partially ligated left carotid artery of fat-fed 
atheroprone mice (ApoE−/−). This approach provides 
a potential means to prevent the formation of 
atherosclerotic lesions [52]. 
Nanoparticle targeting strategies for Stenosis 
Stenosis is mainly caused by luminal narrowing 
of blood vessels due to buildup of atherosclerosis 
plaques inside arterial walls [54]. To treat stenosis, 
balloon dilation and expandable stent placement are 
being used as safe, minimally-invasive, and effective 
treatment options, but over time restenosis of treated 
arteries leads to adverse events such as myocardial 
infarction and blocked peripheral circulation [54].  
For treatment of stenosis post balloon injury 
without delaying healing of damaged endothelial 
cells, Cyrus et al. used αvβ3-targeted 
Rapamycin-loaded paramagnetic theranostic 
nanoparticles [55], which resulted in sustained and 
controlled release of anti-restenotic rapamycin in vitro. 
Restenosis was induced in a rabbit femoral artery 
model through feeding a high-cholesterol diet for 4 
months. Magnetic resonance angiography images 
post two week treatment revealed that injured vessels 
treated with theranostic rapamycin-loaded NPs had 
less plaque formation and lumen occlusion than the 
control conditions [55].  
In another study, to control the dose and release 
kinetics of paclitaxel from a magnetizable stent, 
Chorny et al. used polylactide-based, 
paclitaxel-loaded magnetic nanoparticles 
(PTX-MNPs) under uniform-field–induced 
magnetization for treatment of in-stent restenosis[56]. 
DLS-based measurement showed the MNPs had an 
average hydrodynamic diameter of 263 nm and a -12 
mV zeta potential. Growth of arterial smooth muscle 
cells treated with PTX-loaded MNPs was significantly 
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inhibited compared to the control in a nonmagnetic 
condition. A rat carotid artery model of in-stent 
restenosis was used for local delivery of clinically 
relevant MNP dose under uniform magnetic field, 
which demonstrated accumulation of significantly 
higher MNP amount to the stent and arterial tissue 
than the nonmagnetic control. This approach 
provided a site-specific drug delivery method to 
implanted magnetizable stents by uniform magnetic 
field-controlled targeting of MNPs for the treatment 
of in-stent restenosis [56]. 
Nanoparticle targeting strategies for 
Peripheral Artery Disease  
PAD is a common type of vascular disease which 
is characterized by narrowing of peripheral arteries 
through buildup of plaques commonly seen in lower 
extremities, which reduces blood supply to head, 
organs and limbs. Therapeutic angiogenesis is 
identified as a treatment option for PAD through 
formation of new blood vessels by sprouting and 
branching of existing blood vessels in ischemic tissues 
[57]. Successful angiogenesis is heavily dependent on 
effective and sustained delivery of VEGF to an 
ischemic site. Clinical administration of growth 
factors via bolus injection into either an ischemic site 
or intravenously was employed to induce therapeutic 
angiogenesis but failed to achieve significant 
therapeutic effects, primarily due to poor circulation 
time with the lack of targeting mechanism and 
sustained delivery of growth factors [58].  
Sun et al. developed VEGF-loaded, 
IR800-conjugated, graphene oxide (GO-IR800-VEGF) 
NPs as a theranostic platform for imaging therapeutic 
angiogenesis of ischemic muscle in a mice hind limb 
model [59]. NPs were able to stably deliver a sufficient 
concentration of VEGF to an injury site. The efficacy 
of GO-IR800-VEGF to induce therapeutic 
angiogenesis of ischemic muscle was analyzed by LDI 
PA, and PET as imaging methods, which were further 
validated by ex vivo immunostaining of CD31 and 
α-SMA [59].  
 
 
Figure 4. PREY(GSPREYTSYMPH)-targeted liposome for selectively targeting atheroprone vasculature. A) Ahterosclerosis preferentially develops in the regions of 
disturbed blood flow. PREY peptide (GSPREYTSYMPH) of nanocarrier was selectively accumulated in the luminal surface of endothelial cells caused by the 
atheroprone flow. B) Vascular targeting of PREY-nanocarriers. (i) En face preparations of ligated left carotid arteries with scrambled and targeted liposome injections 
(Red = liposome fluorescence, blue = nuclei). (ii) Cross section of a mouse aortic arch showing targeted liposome accumulation in the lesser curvature of the aortic 
arch (inset) (green = elastin autofluorescence, red = liposome fluorescence; Scale bar = 250 μm, inset scale bar = 100 μm). C) Liposome delivery of 
tetrahydrobiopterin (BH4) significantly reduced plaque burden in the ligated left carotid artery of ApoE-/- mice fed a high fat diet for 7 days. Plaque is outlined in red, 
and lumen is outlined in blue. Scale bars = 100 μm. Reproduced with permission from [52]. 
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In another approach to target a site of PAD 
through an EPR effect, Kim et al. used rhodamine B- 
labeled, PEGylated R-SiNPs for sustained delivery of 
VEGF in a murine model of hind limb ischemia [60]. 
PEGylated NPs with an average diameter of 80 nm 
showed longer blood circulation time and 
preferentially accumulated into ischemic site in a 
uniform fashion as compared to the non-PEGylated 
si-NPs. VEGF loaded, PEGylated NPs demonstrated 
the most efficient targeting ability within a week 
post-ischemia induction [60].  
Nanoparticle targeting strategies for 
Thrombosis 
Thrombosis is an acute medical condition of 
vascular system which is defined by formation of 
abnormal clot inside the blood vessels and obstruction 
in blood flow of the circulatory system [61]. It 
happens through deposition of platelets and fibrin as 
a form of clot to prevent blood loss from injured blood 
vessels. A ruptured clot from an injured blood vessel 
travels through the circulation system; struck 
somewhere; and thus damaged tissue and organ 
substantially [61]. Resorting the anti-thrombotic 
surface of affected vessels is promising treatment 
option for thrombosis [62]. High, specific affinities of 
D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl 
ketone (PPACK) and bivalirudin to thrombin are 
clinically proven but rapid in vivo clearance limits 
their clinical application as an anti-coagulant agent 
[63, 64]. Generation of effective and long-lasting 
anticoagulant surface over a newly forming clot 
through the use of thrombin-targeted NPs provided 
another site-specific approach for management of 
acute thrombosis [64].  
In order to form an anticlotting surface at the site 
of acute thrombosis, Myerson et al. developed either 
PACK or bivalirudin-functionalized perfluorocarbon 
NPs (PFC-NPs) as a thrombin-targeting theranostic 
platform. They demonstrated binding of PFC-NPs 
onto a site of active clotting, thereby quenching the 
local thrombin activity and inhibiting platelet 
deposition while exhibiting only a transient systemic 
anticoagulant effect [65]. A Fibrinopeptide A (FPA) 
ELISA assay confirmed binding of PPACK and 
bivalirudin to thrombin in free as well as when 
attached onto NPs. Thrombin-inhibiting NPS were 
injected into C57BL6 mice post inducing a laser injury 
of the carotid artery. A 19F-based MRI signal 
confirmed uniform accumulation of PFC-NPs in 
arterial thrombi. The specific binding and retention of 
thrombin-inhibiting NPs in injured arteries were 
verified by quantitative 19F spectroscopy [65].  
In a similar manner, Palekar et al. conjugated 
PPACK as an anti-thrombotic agent onto the surface 
of liposomes and formulated it as single unilamellar 
vesicles with an average diameter of 170 nm having a 
nearly neutrally-charged surface [66]. The binding 
and anti-coagulant activity of vesicles was 
demonstrated through in vitro clot growth assays and 
fluorescent imaging. The in vivo efficacy of injected 
PPACK-liposomes as anti-coagulation agent was 
demonstrated by prolonged arterial occlusion time 
compared to controls in a mouse model of 
photochemical-induced carotid artery injury [66].  
Nanoparticle targeting strategies for 
Restenosis 
Restenosis mainly occurs due to remodeling of 
arterial wall through activation, proliferation and 
migration of vascular smooth muscle cells (VSMCs), 
and over production of extracellular matrix after 
balloon-angioplasty [67]. Since activated VSMCs 
express a higher level of tissue factor (TF) at a balloon 
injury site, Lanza et al. used TF–targeted NPs and 
identified angioplasty-induced expression of TF by 
SMCs within tunica media in a porcine carotid 
arteries model [68]. In their fellow-up study, 
TF–targeted biotinylated perfluorocarbon NPs were 
used as a theranostic platform for co-delivery of 
hydrophilic doxorubicin and hydrophobic paclitaxel 
to prevent restenosis since they are potent lipophilic 
anti-proliferative agents [69]. Both drugs-loaded NPs 
were able to successfully reduce VSMC proliferation 
compared to the treated control condition. Specific 
adherence of TF-targeted paclitaxel NPs with a large 
payload of paramagnetic chelates was visualized by 
T1-weighted 1H MRI and detected by 19F 
spectroscopy at 4.7T. However, the theranostic 
function was not confirmed in animal models [69].  
Nanoparticle targeting strategies for Aortic 
Aneurysms  
Aortic aneurysm (AA) is characterized by 
formation of a balloon-like bulge inside either the 
abdominal or thoracic aorta. It mainly occurs through 
vessel enlargement resulting from chronic 
inflammation which causes thinning and weakening 
of all three layers of the vessel wall [70]. Arterial walls 
weaken through calcification and MMP-induced 
degradation of vessel ECM. A survival rate following 
raptured AA balloon was ranged merely between 
10-15 %[70]. To remove the mineral deposit and 
further restore the elastic lamina through therapeutic 
treatment, Nosoudi et al. developed EDTA- and 
PGG-loaded NPs with a particle size of around 200 
nm and ~39 mV ζ- potential as a dual therapeutic 
platform in a rat model of abdominal aortic 
aneurysms [71]. First, EDTA-loaded NPs were 
delivered to reduce calcification by removing calcium 
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chloride in a vessel injury model, followed by delivery 
of pentagalloyl glucose (PGG)-loaded NPs, resulting 
in a reduction in development of calcified aneurysm. 
As a result, macrophage-induced inflammation was 
reduced with consequent decreases in calcification, 
elastin degradation, and MMP activity [71]. 
 These research examples do not cover all the 
recent advances but provide necessary insights into 
the representative efforts done thus far in developing 
nanotheranostic platforms applied as vascular disease 
treatments. The common concept to design 
theranostic nanoparticles enables physicians to 
diagnose and treat vascular diseases simultaneously, 
thereby optimizing drug doses for the individual 
patient in a more efficient manner. These efforts will 
serve as a cornerstone to improve therapeutic and cost 
benefits while reducing adverse side effects [16, 17, 
72]. 
Current limitations and future outlook 
 The current review article highlights recent 
approaches in the development of theranostic NPs to 
enable real-time diagnosis and treatment of vascular 
diseases. Continuing advances in the fields of 
vascular medicine and nanotechnology enables the 
design and utilization of multifunctional NPs for 
effective monitoring of inflammation-related 
dysfunctional changes in endothelium, target-specific 
drug release to lesions, and healing processes such as 
retardation of atherosclerotic plaques or induction of 
thrombolysis. In vitro and in vivo experiments carried 
out in animal models and some preliminary pilot 
studies in humans exhibit promise in achieving these 
objectives [73]. 
Despite recent advances in the development of 
vascular nanotheranostics, there is no commercialized 
product. Main roadblocks include low sensitivity of 
MRI agents (e.g. iron oxide NPs); cost effectiveness 
(gold NPs), complex synthesis, long-term toxicity of 
nanomaterials used; and a lack of human disease 
models [74]. The vast majority of studies have been 
conducted in small animal models that have 
significantly different anatomies of vascular disease 
compared to humans [16]. Although, nanoscale size 
and charge allow for effective internalization of 
nanoparticles into cellular compartments, excessive 
accumulation of particles into tissue also poses 
toxicity risks. Therefore, extensive, prudent 
toxicological and pharmacological studies are 
necessary before considering clinical translation of 
NPs [75].  
Translation from the bench to clinical research 
may be accelerated through tethering of biological 
drugs such as peptide and nucleic acids to 
theranostics and/or application of ex vivo human 
models in combination with organ-on-a-chip 
technologies, human induced pluripotent stem cells 
(iPSCs), and high-throughput screening techniques. 
Collaborative efforts between nanomaterial engineers, 
basic scientists, and clinicians are critical towards 
implementing and translating these technologies to 
achieve positive clinical outcomes. 
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